VivoSim Labs (NASDAQ: VIVS) Among IGC, IVF, UCL, TRUG as

New Post Public Reply Private Reply Replies (0) Message Board
louied91
77
VivoSim Labs (NASDAQ: VIVS) Among IGC, IVF, UCL, TRUG as FDA-Backed Human-Based Testing Gains Momentum

https://thestreetreports.com/vivosim-labs-nas...-momentum/  

August 17, 2026 — VivoSim Labs, Inc. (NASDAQ: VIVS) is gaining investor attention as its 3D human tissue models, artificial intelligence and New Approach Methodologies (NAMs) target one of pharmaceutical development’s biggest challenges: identifying drug toxicity before costly clinical trials.

The opportunity comes as the U.S. Food and Drug Administration (FDA) advances initiatives supporting human-relevant alternatives to traditional animal testing. In 2026, the FDA issued draft guidance addressing the validation and use of NAM technologies, including organoids, spheroids, organs-on-chips and computational models, creating a potentially favorable regulatory environment for companies developing advanced preclinical testing technologies.

VivoSim reported that its NAMkind™ Liver model achieved 91% predictive accuracy, 90% sensitivity and 95% specificity across a 92-compound clinical small-molecule dataset under repeat-dose conditions. The company’s VitroSense™ AI platform, trained using data from its human intestinal models, separately achieved a reported 96% predictive accuracy in its training dataset for potential drug-induced diarrhea.

Alongside VivoSim Labs, Inc. (NASDAQ: VIVS), investors are watching several other stocks seeing active early trading, including INVO Fertility, Inc. (NASDAQ: IVF), uCloudlink Group Inc. (NASDAQ: UCL), TruGolf Holdings, Inc. (NASDAQ: TRUG) and IGC Pharma, Inc. (NYSE American: IGC), with fresh company news adding to investor attention today.

VivoSim is also targeting the growing antibody-drug conjugate (ADC) market, where its liver and intestinal models are being evaluated for their ability to identify toxicity associated with ADC payloads, linkers and other components.

Commercialization is beginning to advance. VivoSim recently announced its first commercial NAMkind sales in mainland China, moving the platform from scientific validation toward paid pharmaceutical applications.

The company has also strengthened its financial position, reporting approximately $10.1 million in cash as of August 3, 2026, following a $5 million milestone payment from Eli Lilly and Company (NYSE: LLY), additional escrow proceeds and a July financing. VivoSim has reiterated guidance for 500%+ revenue growth in fiscal 2027, driven by its expansion of NAM-based contract research services to pharmaceutical companies.

For investors following VIVS stock, AI biotech, drug toxicity testing, 3D human tissue models, FDA animal-testing alternatives, ADC drug development and New Approach Methodologies, the key question is increasingly whether VivoSim can turn predictive human biology into a scalable pharmaceutical research business.

About VivoSim LabsVivoSim Labs, Inc. (NASDAQ: VIVS) provides pharmaceutical and biotechnology companies with 3D human liver and intestinal tissue models for drug testing and toxicology using New Approach Methodologies (NAMs).
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 44

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 0

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Epic Legal Battle Yields $63M Verdict Against Chevron

Updated Category News Views 359

A David vs. Goliath Showdown in Court How's this for a courtroom drama? Picture eight lawyers taking on Chevron over a toxic pit buried beneath an unsuspecting family's home. These folks at Ernst Law Group and Trial Lawyers for Justice tackled Union Oil (now Chevron) and bagged a staggering $63 million for their client. This ain't your run-of-the-mill legal squabble; it's...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 48

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 131

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Lilly Endowment Boosts Military Families with $10M Grant

Updated Category News Views 78

A Game-Changer for Semper Fi & America's Fund Dive in, folks. What we've got here is a hefty chunk of change — $10 million to be precise — dropped into Semper Fi & America's Fund's lap by Lilly Endowment Inc. We're talking about a grant designed to shore up the long-term support system crafted for the brave souls in military families. It’s about time a significant...

Continue Reading
Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 137

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Nasdaq Tumbles: AI Hardware Pulls Markets Down

Updated Category News Views 133

Wall Street's Slide Fueled by AI Nerves The markets got a real jolt on Monday, sending Nasdaq down 2.5% thanks to a sharp dip in AI hardware stocks. Tech tickers tied to artificial intelligence were at the core of a sell-off, knocking the S&P 500 down 1.92% alongside it. Investors are on edge, and it’s not just the weather—it's a real shake-up driven by policy moves...

Continue Reading
Giovanni Recalde Sues County After False Report

Updated Category News Views 199

Justice and Reputation: A Mix-Up Costs Big When the cops screw up, sometimes they really take the cake. That's what Giovanni Recalde learned, the hard way, when his name got tangled in a mess related to a gambling operation he wasn't even a part of. Prince William County police pasted his name into their daily incident report last year like it was no big deal. But it...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 0

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading

Top 5 Most Recently Viewed Articles

Xanadu Mines Expands Funding to $7.5 Million for Growth

Updated Category News Views 267

Xanadu Mines Secures Expanded Funding of $7.5 Million Highlights of the Funding Expansion The recent placement undertaken by Xanadu Mines Ltd, increasing its funding to a total of $7.5 million, marks an essential milestone for the company. This expansion adds $2 million to its initial placement announced earlier in November. The additional capital is critical for Xanadu...

Continue Reading
First Advantage: What Investors Should Know About Recent Changes

Updated Category News Views 312

Recent Developments Regarding First Advantage Corporation First Advantage Corporation (NASDAQ: FA) is experiencing a downturn in share prices following a recent downgrade from Wolfe Research. The company has shifted from an Outperform rating to a Peer Perform rating, raising concerns among investors. The Insights from Wolfe Research Wolfe Research's analysts have...

Continue Reading
Exploring 89bio's Upcoming Fireside Chat at Healthcare Conference

Updated Category News Views 118

89bio's Participation in Healthcare Conferences 89bio, Inc., a pioneer in developing therapies for liver and cardiometabolic diseases, is gearing up for a significant engagement at an upcoming healthcare conference. About the Conference The Leerink Partners Global Healthcare Conference is an important event where stakeholders from the biopharmaceutical field gather. This...

Continue Reading
Transforming Finance Operations: The Rise of Advanced Solutions

Updated Category News Views 175

The Evolution of Finance Outsourcing As business operations continue to evolve rapidly, many companies are expanding their finance and accounting outsourcing services. Increasingly, organizations are looking for specialized skills from their service providers. Recent insights reveal a shift in client expectations, pushing providers to offer a broader range of services...

Continue Reading
Understanding Alliance Pharma's Recent Trading Activities

Updated Category News Views 164

Recent Disclosures from Alliance Pharma plc Alliance Pharma plc, known for its strategic developments in the pharmaceutical sector, has been active in the market, with notable disclosures coming from its exempt principal trader, Investec Bank plc. This recent disclosure falls under the guidelines of Rule 8.5 from the Takeover Code, reflecting a transparent approach to...

Continue Reading